Annamalai Aniyizhai, Singh Noreen, O'Malley Stephanie S
Yale School of Medicine, New Haven, Connecticut.
University of California at San Francisco, Santa Rosa, California.
Yale J Biol Med. 2015 Sep 3;88(3):271-7. eCollection 2015 Sep.
Smoking rates in people with serious mental illness (SMI) are disproportionately high compared to the general population. It is a leading contributor to the early mortality in this population. Smoking cessation rates are low in this group, though patients are motivated to quit. Unfortunately, health care providers do not always prioritize smoking cessation for this population. This review provides an overview of prevalence rates, biological effects that maintain smoking, and evidence-based treatments for smoking cessation in SMI. In addition, objective and qualitative data from a chart review of 78 patients with SMI prescribed smoking cessation treatment at one community mental health center are described. Of these, 30 (38.5 percent) were found to either quit (16/78) or reduce (14/78) smoking. Varenicline appeared to be particularly effective. Review of the literature and results of this study suggest that smoking cessation pharmacotherapies are effective for SMI patients and should be offered to those who smoke.
与普通人群相比,严重精神疾病(SMI)患者的吸烟率高得不成比例。吸烟是导致该人群过早死亡的主要因素。尽管患者有戒烟的动机,但该群体的戒烟率很低。不幸的是,医疗保健提供者并不总是将该人群的戒烟作为优先事项。本综述概述了SMI患者的吸烟率、维持吸烟的生物学效应以及基于证据的戒烟治疗方法。此外,还描述了对一家社区心理健康中心78名接受戒烟治疗的SMI患者病历审查的客观和定性数据。其中,30名(38.5%)患者被发现要么戒烟(16/78),要么减少了吸烟量(14/78)。伐尼克兰似乎特别有效。文献综述和本研究结果表明,戒烟药物疗法对SMI患者有效,应该提供给吸烟的患者。